(4-苯基-1,3-噻唑-2-基)硫脲 | 7709-31-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: (4-苯基-1,3-噻唑-2-基)硫脲
• 英文名称: N'-(4-phenylthiazol-2-yl)thiourea
• 英文别名: N-(4-phenyl-2-thiazolyl)thiourea；N-(phenyl-2-thiazolyl)thiourea；(4-phenyl-thiazol-2-yl)-thiourea；N-(4-phenyl-1,3-thiazol-2-yl)thiourea；(4-Phenyl-thiazol-2-yl)-thioharnstoff；N'-(4-Phenylthiazolyl)-thioharnstoff；(4-Phenyl-1,3-thiazol-2-yl)thiourea
• CAS: 7709-31-1
• 化学式: C₁₀H₉N₃S₂
• mdl: MFCD03145869
• 分子量: 235.334
• InChiKey: UCIPRGBBFKCVEY-UHFFFAOYSA-N

物化性质

• 熔点：
  211-212 °C (decomp)
• 沸点：
  431.4±38.0 °C(Predicted)
• 密度：
  1.421±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  111
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (4-苯基-1,3-噻唑-2-基)硫脲 在 sodium ethanolate 作用下， 以 乙醇 为溶剂， 生成 4-[2-(5-oxo-4,4-diphenyl-2-thioxo-imidazolidin-1-yl)-4-phenyl-thiazol-5-ylazo]-benzenesulfonamide
  参考文献：
  名称：

  Dhal,P.N. et al., Journal of the Indian Chemical Society, 1973, vol. 50, p. 680 - 684

  摘要：

  DOI：
• 作为产物：
  描述：

  2-氨基-4-苯基噻唑 在 sodium hydroxide 作用下， 以 丙酮 为溶剂， 反应 1.33h， 生成 (4-苯基-1,3-噻唑-2-基)硫脲
  参考文献：
  名称：

  Dhindsa, G. S., Polish Journal of Chemistry, 1986, vol. 60, # 4-6, p. 609 - 614

  摘要：

  DOI：

文献信息

• Complexes of N′-(4-phenyl thiazole-2-yl) thiourea with some first row transition metals
  作者：K.C. Satpathy、H.P. Mishra、R. Mishra

  DOI：10.1016/0022-1902(81)80614-8

  日期：1981.1

  Metal complexes of N′-(4-phenyl thiazole-2-yl) thiourea (L) possessing the stoichiometry, [MLX2] (M = Cu2+; X = Cl−, Br−, NO3− and ClO4−), (M = Ni2+; X = Cl−), (M = Co2+; X = Cl−, NO3−) have been isolated and studied. Tentative geometry of the complexes has been deduced by elemental analyses, magnetic and spectroscopic techniques. Fungicidal screening of the complexes has been made against Helminthosporium

  的N'金属配合物-具有化学计量（4-苯基噻唑-2-基）硫脲（L），[MLX 2 ]（M =铜2+ ; X =氯- ，溴-，NO 3 -和C10 4 -），（M =倪2+ ; X =氯- ），（M = CO 2 + ; X =氯-，NO 3 - ）已被分离和研究。配合物的初步几何形状已通过元素分析，磁性和光谱技术推论得出。已对米曲霉，尖孢镰刀菌和黑曲霉进行了复合物的杀真菌筛选。
• Guanidine Compounds, and Use Thereof as Binding partners for 5-Ht5 Receptors
  申请人：Netz Astrid

  公开号：US20070299074A1

  公开（公告）日：2007-12-27

  The present invention relates to guanidine compounds of the general formula I corresponding enantiomeric, diastereomeric and/or tautomeric forms thereof as well as pharmaceutically acceptable salts thereof. The present compound further relates to the use of guanidine compounds as binding partners for 5-HT5 receptors for the treatment of diseases which are modulated by a 5-HT5 receptor activity, in particular for the treatment of neurodegenerative and neuropsychiatric disorders as well as the associated signs, symptoms and dysfunctions.

  本发明涉及通式I的胍化合物及其对应的对映异构体、顺反异构体和/或互变异构体，以及其药学上可接受的盐。本化合物进一步涉及胍化合物作为5-HT5受体的结合伴侣，用于治疗受5-HT5受体活性调节的疾病，特别是用于治疗神经退行性和神经精神障碍以及相关的症状、症候和功能障碍。
• GUANIDINE COMPOUNDS, AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS
  申请人：Netz Astrid

  公开号：US20110237589A1

  公开（公告）日：2011-09-29

  The present invention relates to guanidine compounds of the general formula I corresponding enantiomeric, diastereomeric and/or tautomeric forms thereof as well as pharmaceutically acceptable salts thereof. The present compound further relates to the use of guanidine compounds as binding partners for 5-HT5 receptors for the treatment of diseases which are modulated by a 5-HT5 receptor activity, in particular for the treatment of neurodegenerative and neuropsychiatric disorders as well as the associated signs, symptoms and dysfunctions.

  本发明涉及一般式I的胍化合物，其对应的对映异构体、顺反异构体和/或互变异构体以及其药学上可接受的盐。本化合物进一步涉及将胍化合物用作5-HT5受体的结合伴侣，用于治疗由5-HT5受体活性调节的疾病，特别是用于治疗神经退行性和神经精神障碍以及相关的症状、症候和功能障碍。
• Guanidine compounds, and use thereof as binding partners for 5-HT5 receptors
  申请人：Netz Astrid

  公开号：US08481576B2

  公开（公告）日：2013-07-09

  The present invention relates to guanidine compounds of the general formula I corresponding enantiomeric, diastereomeric and/or tautomeric forms thereof as well as pharmaceutically acceptable salts thereof. The present compound further relates to the use of guanidine compounds as binding partners for 5-HT5 receptors for the treatment of diseases which are modulated by a 5-HT5 receptor activity, in particular for the treatment of neurodegenerative and neuropsychiatric disorders as well as the associated signs, symptoms and dysfunctions.

  本发明涉及一般式I的胍化合物及其对应的对映异构体、顺反异构体和/或互变异构体，以及其药学上可接受的盐。本化合物进一步涉及将胍化合物用作5-HT5受体的结合伴侣，用于治疗5-HT5受体活性调节的疾病，特别是用于治疗神经退行性和神经精神障碍以及相关的症状、症候和功能障碍。
• Swathi; Kumar, T. Durai Ananda; Haribabu, Indian Journal of Heterocyclic Chemistry, 2012, vol. 22, # 1, p. 41 - 46
  作者：Swathi、Kumar, T. Durai Ananda、Haribabu、Subrahmanyam

  DOI：——

  日期：——